Related Experiment Video
Updated: Jun 28, 2025
08:00
The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
Published on: April 16, 2019
18.0K
Dexamethasone in Patients with Glioblastoma: A Systematic Review and Meta-Analysis
Pierre Scheffler1, Christian Fung1, Shahan Momjian2
1Department of Neurosurgery, Medical Center University of Freiburg, 79098 Freiburg, Germany.
Cancers
|April 13, 2024
Summary
Dexamethasone use in glioblastoma patients is linked to worse survival outcomes. This study suggests restricting dexamethasone to specific symptomatic cases, highlighting the need for further research.
Area of Science:
- Neuro-oncology
- Clinical pharmacology
Background:
- Glioblastomas are aggressive brain tumors with poor prognoses.
- Dexamethasone is commonly used to manage brain edema but lacks strong evidence.
Purpose of the Study:
- To systematically review and meta-analyze evidence on dexamethasone use in glioblastoma patients.
- To evaluate the impact of dexamethasone on overall survival (OS) and progression-free survival (PFS).
Main Methods:
- Systematic review and meta-analysis following PRISMA-P guidelines.
- Searched PubMed, Web of Science, Cochrane Library, and Academic Search Premier for relevant studies.
- Included 22 retrospective studies assessing OS and PFS with varying dexamethasone doses.
Main Results:
- Higher dexamethasone doses correlated with poorer OS (HR 1.62) and PFS (HR 1.49).
- Worse OS persisted even after adjusting for clinical status (HR 1.52).
Conclusions:
- Dexamethasone use in glioblastoma is associated with worse long-term outcomes.
- Administration should be limited to carefully selected symptomatic patients.
- Prospective studies are essential to validate these findings.
